South Dakota is currently home to 344 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Sioux Falls, Rapid City, Watertown and Aberdeen. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895
Recruiting
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Sanford Hematology Oncology-Sioux Falls SD ( Site 0012), Sioux Falls, South Dakota
Conditions: Advanced Solid Neoplasms
Register for Updates
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Health Concepts, Rapid City, South Dakota
Conditions: Plaque Psoriasis
Register for Updates
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936
Recruiting
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Lymphoma
Register for Updates
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Sanford Cancer Center ( Site 1951), Sioux Falls, South Dakota
Conditions: Melanoma
Register for Updates
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691
Recruiting
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: Breast Cancer
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Black Hills Cardiovascular Research, Rapid City, South Dakota
Conditions: Atrial Fibrillation
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Monument Health Clinical Research, Rapid City, South Dakota
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383
Recruiting
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), n... Read More
Gender:
All
Ages:
Between 40 years and 79 years
Trial Updated:
04/23/2024
Locations: Care Access Rapid City, Rapid City, South Dakota
Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Avera Cancer Institute, Sioux Falls, South Dakota
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/23/2024
Locations: Rapid City Medical Center, LLC, Rapid City, South Dakota
Conditions: Ulcerative Colitis
Register for Updates
A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825
Recruiting
A Phase 2 study to evaluate the clinical activity, safety, and potentially predictive biomarker profile of ZN-c3 in subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Site 0260 - Monument Health Rapid City Hospital, Rapid City, South Dakota
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Register for Updates
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862
Recruiting
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the ef... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Prairie Lakes Healthcare System, Watertown, South Dakota
Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates